EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut–Liver Axis, Microbiota, Bile Acids, and Immune Response in Pathogenesis of Primary Sclerosing Cholangitis: An Overview

Fotios S Fousekis, Konstantinos Mpakogiannis, Georgios D Lianos iD, Elisabetta Antonelli iD, Gabrio Bassotti iD, Konstantinos H Katsanos

Journal of Clinical Medicine · 03.11.2025 · 14 (21) · 7817

DOI: 10.3390/jcm14217817 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.11.2025. Verfasst von Fotios S Fousekis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease characterized by progressive bile duct inflammation and fibrosis. Its strong association with inflammatory bowel disease (IBD) highlights the possible role of the gut–liver axis in disease pathogenesis. Here, we review the mechanisms that may contribute to the disruption of the gut–liver axis, leading to liver injury and the development of PSC. In particular, disruption of the intestinal barrier allows microbial products to enter the portal circulation, stimulating hepatic immune cells and triggering biliary inflammation. Concurrently, gut-primed lymphocytes expressing mucosal homing receptors migrate aberrantly to the liver, where they may contribute to biliary epithelial cell injury. Dysbiosis, characterized by reduced microbial diversity and the expansion of bile-tolerant and pro-inflammatory taxa, amplifies this immune activation and disturbs gut–liver homeostasis. Moreover, bile acids act as signaling molecules, regulating metabolism and immune responses through receptors such as FXR and TGR5. Dysregulation of these pathways may promote cholestasis, inflammation, and fibrosis. By understanding these interactions, we may identify novel therapeutic targets for PSC.

Schlagwörter

Stichwörter der Autor:innen

dysbiosisfibrogenesisgutimmune activationinflammationintestinal barriermicrobiomeprimary sclerosing cholangitis

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
  • Department of Surgery, University Hospital of Ioannina, 45500 Ioannina, Greece.
  • Gastroenterology, Hepatology and Digestive Endoscopy Section, Department of Medicine and Surgery, University of Perugia Medical School, 06123 Perugia, Italy.

ORCID-Profile: Georgios D Lianos, Elisabetta Antonelli, Gabrio Bassotti

Zitieren

APA

Fousekis, F. S., Mpakogiannis, K., Lianos, G. D., Antonelli, E., Bassotti, G., & Katsanos, K. H. (2025). Gut–Liver Axis, Microbiota, Bile Acids, and Immune Response in Pathogenesis of Primary Sclerosing Cholangitis: An Overview. Journal of Clinical Medicine, 14(21), 7817. https://doi.org/10.3390/jcm14217817

Vancouver

Fousekis FS, Mpakogiannis K, Lianos GD, Antonelli E, Bassotti G, Katsanos KH. Gut–Liver Axis, Microbiota, Bile Acids, and Immune Response in Pathogenesis of Primary Sclerosing Cholangitis: An Overview. Journal of Clinical Medicine. 2025;14(21):7817. doi:10.3390/jcm14217817

BibTeX
@article{Fousekis2025,
  author = {Fousekis, Fotios S and Mpakogiannis, Konstantinos and Lianos, Georgios D and Antonelli, Elisabetta and Bassotti, Gabrio and Katsanos, Konstantinos H},
  title = {Gut–Liver Axis, Microbiota, Bile Acids, and Immune Response in Pathogenesis of Primary Sclerosing Cholangitis: An Overview},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {21},
  pages = {7817},
  doi = {10.3390/jcm14217817}
}
Kostenlos starten →